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ABSTRACT
Feeding Female Growing Rats Different Sources of Omega-3 Polyunsaturated Fatty
Acids Affects Lung Fatty Acid Composition and Gene Expression
Maria L. Dalzot

Justification: The lungs are constantly exposed to oxidative stress and inflammation
which increase the risk of lung damage. Omega-3 polyunsaturated fatty acids (n-3
PUFAs), found in different dietary sources, regulate the expression of various genes
involved in eicosanoid production and oxidative stability.
Objective: to determine whether providing different sources of n-3 PUFAs will affect the
fatty acid composition, inflammation and oxidation in the lungs of growing rats.
Methods: Growing (age 28 d) Sprague-Dawley rats were randomly assigned
(n=10/group) to diets consisting of either corn oil (CO) or n-3 PUFA rich flaxseed (FO),
krill (KO), salmon (SO) or tuna (TO) oil for 8 weeks. Diet and tissue fatty acid
composition was analyzed by gas chromatography. The enzymes involved in eicosanoid
synthesis, 5-lipoxygenase (5-LOX) and cyclooxygenase II (COX II), and the antioxidant
enzymes, catalase (CAT), glutathione peroxidase (GSH-Px) and superoxide dismutase 1
(SOD1), were determined using real-time polymerase chain reaction.
Results: Rats fed FO, with the highest alpha-linolenic acid (ALA, 18:2n-3) content, had
the highest (P<0.001) lung ALA deposition. Rats fed KO, with the highest
eicosapentaenoic acid (EPA, 20:5n3) content, had the highest (P<0.001) lung EPA
deposition compared to all diet groups, except SO-fed rats. Rats fed TO, with the highest
docosahexaenoic acid (DHA, 22:6n-3) content, had the highest (P<0.001) lung DHA
deposition compared to rats fed CO or FO. The relative expression of 5-LOX was
significantly up-regulated (P=0.007) in rats fed FO compared to CO-fed rats. Expression
of the antioxidant defense enzyme, SOD1 was down-regulated (P=0.01) in TO-fed rats
compared to rats fed CO. Dietary TO has an EPA/DHA ratio of 1:2 and had a higher
(P<0.001) lung DHA content compared to rats fed CO.
Significance: The fatty acid composition of the lungs reflected dietary intake. The
increase in ω-3 PUFAs in lung tissue may affect the risk of lung damage, and in turn,
susceptibility to lung diseases by altering gene expression of inflammation and oxidative
stability.
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INTRODUCTION
The long-chain omega-3 polyunsaturated fatty acids (ω-3 PUFAs), primarily

eicosapentaenoic acid (EPA, 20:5 -3) and docosahexaenoic acid (DHA, 22:6 -3), found
in fatty fish and fish oils, have been extensively studied for their protective effects in
cardiovascular disease as well as for their roles in growth and development (Egert, 2009;
Yang, 1994). Eicosanoids derived from EPA and DHA have also been shown to be
involved in homeostatic regulation of the lungs and to play a role in respiratory diseases
(Craig-Schmidt et al., 1987). The prevalence of respiratory diseases among infants and
adults is increasing (Christie et al., 1999). Therefore, it is important to determine novel
interventions that have the ability to prevent or modify the course of lung disease. A
potential area is the contribution of dietary consumption of ω-3 PUFAs for the prevention
of lung inflammation and disease.
The ω-3 PUFAs have been shown to reduce inflammatory effects through
competitive inhibition of the enzymes necessary for the production of pro-inflammatory
eicosanoids from the omega-6 polyunsaturated fatty acids (ω-6 PUFAs). The ω-6 PUFA,
arachidonic acid (AA, 20:4 -6) is the precursor to the 2 and 4-series eicosanoids which
include thromboxane A2 (TXA2) and the pro-inflammatory prostaglandin E2 (PGE2) and
leukotriene B4 (LTB4). EPA competes for the same cyclooxygenase II (COX II) enzyme
as the -6 PUFA, AA. Thereby, increasing dietary EPA reduces the synthesis of 2-series
PGE2 and increasing the synthesis of the less reactive 3-series prostaglandins and
thromboxanes. Previous studies have focused on the eicosanoids produced by the
cyclooxygenase pathway. However, leukotrienes, products from the 5- lipoxygenase (5LOX) pathway, also warrant study because leukotrienes are known to be elevated in

1

respiratory diseases such as asthma and cystic fibrosis (O’Driscoll, 1982). The ω-3
PUFA, EPA, competes for the same 5-LOX enzyme as the -6 PUFAs, AA. Thereby,
increasing dietary EPA reduces the synthesis of 4-series leukotrienes and increases the
synthesis of the less reactive 5-series leukotrienes.
Craig-Schmidt et al. (1987) found that it was possible to modulate lung
prostanoids (prostaglandins and thromboxanes) by manipulating the ω-6/ω-3 ratio in the
diet of broiler chickens. The production of 2-series eicosanoids was decreased when
dietary alpha-linolenic acid (ALA, 18:3 -3), provided as flaxseed oil, was increased.
Fritsche and Johnston (1990) demonstrated that feeding a diet rich in ALA to rodents
resulted in reducing lung and extra-pulmonary metastases.
Flaxseed is the richest source of ALA (Cunnane, 1995); however, data indicate
that the biological conversion of ALA to the ω-3 PUFAs, EPA and DHA, is low
(Simopoulos, 2008). Fish oils are rich sources of pre-formed EPA and DHA. Thus,
flaxseed may elicit less biological activity than fish oils rich in EPA and DHA. However,
fish oils differ in the amount and ratio of EPA and DHA (Tou et al., 2011). Additionally,
in fish and plant sources, the ω-3 PUFAs are mainly associated with triglycerides.
However, krill oil fatty acids are mainly in the form of phospholipids (Gigliotti et al.,
2010). This is significant because ω-3 PUFAs associated with phospholipids may be
more bioavailable and more stable against lipid peroxidation than triglycerides (Song et
al., 2000).
Alterations in the fatty acid composition may have significant effects on cell
membranes. However, due to numerous double bonds, ω-3 PUFAs are also susceptible
to lipid peroxidation and may cause a decrease in the concentration of antioxidants in
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animal tissues (Song et al., 2000). Therefore, oxidative stability is also important to
consider before recommending supplementation of the diet with different sources of ω-3
PUFAs. The effect of ω-3 PUFA intake on lipid peroxidation has produced inconsistent
results of increased oxidation (Song et al., 2000; Song and Miyazawa, 2001; Yuan and
Kitts, 2003), no effect on oxidation (Calviello, 1997) and even decreased oxidation
(Demoz et al., 1992).
The lungs are particularly susceptible to oxidative stress due to constantly being
exposed to inhaled air (Wright, 2003). Several pulmonary diseases have been linked to
an imbalance in the oxidant and antioxidant state in the lungs resulting in severe
pulmonary inflammation (Lang et al., 2002). The objective of the study was to determine
whether providing different sources of ω-3 PUFAs will affect fatty acid composition,
inflammation and oxidative stability in the lungs of growing female rats.
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STUDY OBJECTIVES
2.1

Hypothesis
Consuming diets rich in ω-3 PUFAs will alter lung fatty acid composition

and decrease the gene expression of the pro-inflammatory enzymes involved in
eicosanoid synthesis without increasing oxidative stress.
2.2

Study Objectives
1. To determine the effect of feeding different sources of -3 PUFAs on
lung lipid composition in growing female rats.
2. To determine the effect of feeding different sources of ω-3 PUFAs on
expression of the mediators of inflammation, COX II and 5-LOX, in
the lungs of growing female rats.
3. To determine the effect of feeding different sources of ω-3 PUFAs on
oxidative stability in the lungs of growing female rats.
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3

LITERATURE REVIEW
3.1

Pulmonary Physiology
The respiratory system is a highly integrated system that is composed of

the lungs, conducting airways that lead into the lungs and the respiratory muscles
of the thorax. These structures work together to deliver oxygen from the
environment into the tissues.
3.1.1 Anatomy
According to the American Lung Association, the human thoracic
cavity is divided into two chambers that hold the right and left lung by the
mediastinum, where vital organs including the heart, thymus gland, the
trachea, the esophagus and the lymph nodes are located. The human lung
is between 25 and 30 centimeters long and is covered by a protective
membrane called the visceral pleura (Hlastala and Berger, 2001). The
right lung is slightly larger than the left lung and has three lobes (upper,
middle and lower) that are separated into ten segments. The left lung is
smaller because the heart is on the left and is divided into two lobes (upper
and lower) composed of nine segments. In contrast, a rat has five lung
lobes: one left lobe and four right lobes (Suckow et al., 2006). However,
the anatomical structure of a rat's upper respiratory system is analogous to
that of a typical mammal.
As described by Hlastala and Berger (2001), mammalian airways
begin in the nasal passage, which has three major functions: trap inhaled
particles, heat and humidify inspired air. The passage then opens into the
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pharynx and air passes through the larynx and the trachea, the largest
airway. The trachea has C-shaped discs made out of cartilage that
function to keep the airways open. The airways proceed in a branching
pattern dividing the trachea into two main branches, the right and left
bronchi, each entering the right and left lung, respectively. The bronchus
in each lung continues to branch into more narrow airways termed
bronchioles. The terminal bronchioles have smooth muscles rather than
cartilage covering their walls. This allows for adjustment of lung diameter.
During asthma, constriction of these terminal bronchioles in response to
an allergen decreases the airway diameter. After the terminal bronchioles,
the function of the respiratory system transitions from conduction to gas
exchange (Hlastala and Berger, 2001).
As reviewed by Hlastala and Berger (2001), the functional unit of
the respiratory system is called the acinus, the smallest collection of parts
that will perform the basic function of the system, i.e. gas exchange. The
acinus is broken up into three parts: the respiratory bronchioles, the
alveolar ducts and the alveolar sacs. The respiratory bronchioles have
sparse alveoli on their surface. The alveolar ducts are tubes where the
walls are completely covered in alveoli. The alveolar sacs are the terminal
component of the bronchial tree. The alveolar sacs are accumulations of
alveoli with no smooth muscle or connective tissue. The walls of the
alveoli have a diameter of about 0.1 μm and a large surface area to provide
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for easy gas exchange between the air in the alveoli and the blood in the
pulmonary capillaries (Hlastala and Berger, 2001).
The cells of the alveoli have a layer of water that forms a lining on
the cell and causes a high surface tension. To pull air into the lungs, the
air sacs must be expanded. However, due to the high surface tension of
the small alveoli, a surface active agent must be added to reduce the
surface tension of the alveoli. The Type II alveolar cells produce the
surface active agent known as surfactant. Surfactant is made up of 7080% phospholipids, primarily dipalmitoylphosphatidylcholine (Nkadi et
al., 2009). In many mammals, surfactant is composed of mostly
monounsaturated phospholipids. In the rat, surfactant has high
polyunsaturated phospholipid content (Suckow et al., 1996). Survival
depends on producing surfactant in the lungs.
3.1.2 Function
Nelms et al. (2007) described that the primary function of the lungs
is to deliver sufficient amounts of oxygen from the external environment
into the tissues. This involves a need for the arterial blood to have enough
oxygen to meet the body’s metabolic demands and enough energy for the
movement of gas into and out of the lungs. Gas exchange occurs via
passive diffusion. The barrier between gas and blood has a large surface
area and is extremely thin so that gas exchange can take place under
severe demands of oxygen.
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The human lungs undergo a period of growth and maturation
during the first two decades of life. By 10-12 years of age the maximal
number of alveoli is attained. Full maturation of the respiratory system is
achieved by age 20 for females and 25 for males (Nelms et al., 2007). In
the rat, lungs mature over a period of two years (Harding and Pinkerton,
1982).
Aging is associated with a progressive decrease in lung function;
however, unless affected by disease, the lungs are capable of providing
adequate gas exchange during the entire lifespan (Nelms et al., 2007). The
major functional changes are an increase in lung compliance, a decrease in
chest wall compliance (increased stiffness) and reduction in respiratory
muscle strength (Harding and Pinkerton, 1982).
Removing carbon dioxide (CO2) that is produced by cellular
metabolism is another major gas exchange function of the respiratory
system. CO2, like oxygen, moves by diffusion from the cells to the
capillaries where it is transported via the right heart to the lungs for release
into the atmosphere during exhalation (Hlastala and Berger, 2001).
The lungs are also important in the body's defense against infection
and other destructive environmental factors. The nose is the first line of
defense against inhaled harmful materials. The lungs provide the second
line of defense. The cells that line the trachea, bronchi and bronchioles
contain cilia which beat with a rhythm that is fast and forceful enough to
propel mucus and unwanted cells upward toward the pharynx where they

8

can be coughed out or swallowed. The epithelial surface of the alveoli
contains macrophages or scavenger cells that engulf and destroy inhaled
bacteria (Nelms et al., 2007).
Surfactant also has a role in lung function as a host defense
mechanism. According to Wright (2003), the host’s response to
inflammation may be dependent upon the relative proportions of the
surfactant phospholipids within the air space. The surfactant-associated
proteins, SP-A and SP-D, bind to a variety of pathogens. The surfactantassociated proteins enhance uptake by macrophages and may influence the
production and secretion of inflammatory cytokines and superoxide
radicals from inflammatory cells (Wright, 2003). Studies in which various
bacteria and viruses were administered to SP-A-deficient mice show an
enhanced pulmonary inflammatory reaction and an increased release of
the proinflammatory cytokines, tumor necrosis factor-alpha (TNF-α) and
interleukin-6 (IL-6) into the airways (Spragg and Lewis, 2001).
3.2

Lung Inflammation
Inflammation has an influential role in the pathogenesis of respiratory

diseases such as pulmonary fibrosis, chronic obstructive pulmonary disease
(COPD) and acute respiratory distress syndrome (ARDS). The rat model mimics
many features of human asthma and acute lung injury. Therefore, many models
of lung disease have used rat lungs and/or rat cells (National Heart, Lung, and
Blood Institute, 1999).
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Almost all types of pulmonary disease can be classified as either
restrictive pulmonary disease or obstructive pulmonary disease. Restrictive
pulmonary diseases cause an increase in the elastic resistance or decreased
compliance of the lungs. Under normal conditions, the lungs and the thorax are
compliant. However, there is decreased compliance in a diseased state. The
classic example of a disease that decreases lung compliance is pulmonary fibrosis.
The tissues of the lungs become fibrous, scarred and inelastic, making it more
difficult to inflate the lungs and the amount of work to breathe greater (National
Heart, Lung, and Blood Institute, 1999).
Obstructive pulmonary diseases are classified as asthma, chronic
bronchitis and emphysema. The chronic inflammation in these diseases causes an
increase in airway hyper-responsiveness, which is distinguished by a heightened
sensitivity of the airways’ ability to narrow after being exposed to a constrictor
agonist (O'Byrne, 2003). Many pulmonary diseases have been linked to oxidative
tissue injury in the lungs (Kinnula and Crapo, 2003).
3.3

Oxidative Stress
Oxidative stress is a state of imbalance between the body’s antioxidant

and pro-oxidant mechanisms that results in high levels of reactive oxygen species
(ROS). Examples of ROS include, but are not limited to, superoxide, hydrogen
peroxide, hydroxyl radicals and nitric oxide. As levels of ROS rise, damage can
result due to enzyme inactivation, DNA destruction or membrane damage.
Infections and inflammation can trigger oxidative stress (McKee and McKee,
2009; Lang et al, 2002).

10

The lungs are particularly susceptible to oxidative stress due to its unique
structure. The lungs reside at the border of the internal environment and the
external environment, and have a vast surface area that is susceptible to
pathogens, allergens and pollutants found in the 11,000 liters of daily inhaled air
(Wright, 2003). Several pulmonary diseases have been linked to an imbalance in
the oxidant and antioxidant state in the lungs resulting in severe pulmonary
inflammation (Lang et al., 2002).
Patients suffering from COPD, ARDS and asthma have been shown to
have significantly lower plasma levels of the antioxidants vitamin E, vitamin C,
beta-carotene and selenium (Kinnery et al., 2006), as well as plasma ascorbate
and ubiquinol (Lang et al., 2002). Lang et al., (2002) found a decrease in
pulmonary inflammation with a reduced production of oxidants when an enteral
formula supplemented with EPA was administered to ARDS patients. Therefore,
the next sections will discuss dietary fatty acids and their potential antiinflammatory role in the lungs and oxidative stability.
3.4

Omega-6 and Omega-3 PUFAs
It has been estimated that the present Western diet has a ω-6 to ω-3 ratio

of 15–20:1. This is significantly higher than the recommended serum 4:1 ratio
suggested for general health (Simopoulos, 2008).
Alpha- linolenic acid (ALA, 18:3ω-3) and linoleic acid (LA, 18:2ω-6) are
essential fatty acids. Essential is defined as the inability of the human body to
synthesize the nutrients required for proper physiological functioning. Due to the
absence of the desaturase enzymes, delta 12 and 15 desaturase required for de
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novo synthesis, humans must obtain ALA and LA through the diet (Ratnayake
and Galli, 2009). LA can be found in most vegetable oils. Rich food sources of
ALA include soybean oil, canola oil and particularly, flaxseed oil (Cunnane,
1995). Therefore, the proposed study will use corn oil as a source of LA and
flaxseed as a source of ALA.
The essential fatty acid, LA, may be converted to long-chain ω-6 PUFA,
arachidonic acid (AA, 20:4ω-6) and the essential fatty acid, ALA, may be
converted to the long chain ω-3 PUFA, eicosapentaenoic acid (EPA, 20:5 -3) and
docosahexaenoic acid (DHA, 22:6 -3), through sequential enzymatic steps:
elongation, desaturation, and -oxidation (Fig. 1). EPA and DHA can be
synthesized by mammals from ALA; however, conversion of dietary ALA into
EPA and DHA is limited because the efficiency of ω-3 LC-PUFA synthesis
decreases down the cascade of ALA conversion (Galli and Calder, 2009). EPA
and DHA are readily available from fatty fish. Salmon, tuna, menhaden and krill
oil are commercially available sources of ω-3 PUFAs supplements (Tou et al.,
2011).
EPA and DHA play a vital role in many metabolic processes. Many of
EPA’s metabolic effects are produced through conversion to eicosanoids.
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Omega-6
Linoleic Acid

Alpha-linolenic Acid

18: 2ω-6

18: 3ω-3

Gamma-linolenic Acid

Octadecatetraencic Acid

18: 3ω-6

18: 4ω-3

Dihomo-gamma-linolenic Acid

Eicosatetraenoic Acid

20: 3ω-6

20: 4ω-3

Eicosapentaenoic Acid (EPA)

Arachidonic Acid (AA)

20: 5ω-3

20: 4ω-6

2-series
COX
Prostaglandins
Thromboxanes

LOX
Leukotrienes

3-series
COX
Prostaglandins
Thromboxanes

LOX
Leukotrienes

Docosahexaenoic
Acid (DHA)
22: 6ω--3

Figure 1: Essential Fatty Acid Metabolic Pathway
3.5

Eicosanoid Synthesis
Eicosanoids are hormone-like signaling molecules derived from the

oxidation of the twenty-carbon -3 PUFAs, AA and EPA. Eicosanoids mainly
function in inflammation or immunity, and act as messengers in the central
nervous system. The ω-6 eicosanoids are generally pro-inflammatory, whereas
the ω-3s are less reactive. Therefore, the amounts and balance of -6 and -3
PUFAs affect the body's eicosanoid concentration and in turn, the different
eicosanoids affect normal lung physiology as well as influencing risk for lung
diseases.
There are three main types of eicosanoids: prostaglandins, thromboxanes
and leukotrienes. The thromboxanes play a role in vasoconstriction, and the
prostaglandins and leukotrienes play a role in inflammation. The series-2
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prostaglandins (PGE2) and series-4 leukotrienes (LTB4) derived from AA are
involved in vasoconstriction and the synthesis of mediators of inflammation in
response to physiological stress. The series-3 prostaglandins (PGE3) and series-5
leukotrienes (LTB5) derived from EPA are less physiologically potent than
eicosanoids derived from AA (Simopoulos et al., 1999). Therefore, EPA
competing for the same enzymes as AA reduces synthesis of pro-inflammatory
PGE2 and increases the synthesis of less inflammatory ω-3 eicosanoids.
The reduced inflammatory effects of ω-3 fatty acids were originally
recognized as properties of the eicosanoids produced from the cyclooxygenase
and 5-lipoxygenase pathways. However, more recent studies have investigated
reduced production of cytokines as a potential mechanism (Blok et al., 1996).
3.6

Cytokines
Cytokines are small proteins that are involved in intracellular

communication and regulation of immunity. During acute bacterial lung
infection, the release of cytokines promotes the recruitment and activation of
macrophages and neutrophils. Although these cells are important in host defense
against pathogens, dysregulation of immune response can cause local tissue
damage because the cells produce free radicals and ROS (Cheng et al., 2007;
Tiesset et al., 2009).
TNF-α is considered a pro-inflammatory cytokine produced from
phagocytic cells that mediate the host’s response to inflammatory stimuli (Blok et
al, 1996). In a study conducted on inflammatory markers detected in COPD, a
diet high in the ω-3 PUFA, ALA, decreased production of TNF-α which produces
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a variety of inflammatory mediators that affect the bronchial epithelial cells
(Matsuyama et al., 2005).
The anti-inflammatory properties of ω-3 PUFAs are partially mediated by
interaction with peroxisome proliferator-activated receptors (PPAR). PPAR are
expressed in various types of cells that play important roles in inflammation and
immunity. PPARα is abundant in macrophages, monocytes and endothelial cells,
and PPARγ is abundant in alveolar epithelial cells and the bronchial sub-mucosa
(Simon et al., 2006). Ligands of PPARα and PPARγ inhibit the expression of
pro-inflammatory genes in response to cytokine activation. This effect is
dependent upon transcription factor nuclear factor kappa B (NF-кB) activation
(Tiesset et al., 2009). NF-кB is a critical regulator of innate immune responses,
including the pro-inflammatory cytokines (Uddin and Levy, 2010). Cheng et al.
(2007) indicated that inhibition of NF-кB activation in airway epithelium reduces
lung inflammation and injury induced by the gram-negative bacteria
lipopolysaccharide. The ω-3 PUFAs influence the regulation of eicosanoids and
cytokines; therefore, the next section discusses the role of ω-3 fatty acids on lung
inflammation.
3.7

Omega-3 Fatty Acids and Respiratory Inflammation
The relationship between ω-3 PUFAs and pulmonary disease was

suggested by the observation that Inuits living in Greenland had a lower
prevalence of bronchitis and asthma than Inuits living in Denmark (Horrobin,
1987). This observation was hypothesized to be due to the consumption of large
quantities of oily fish that are rich in the ω-3 fatty acids, EPA and DHA by the
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Greenland Inuits (Horrobin, 1987). The eicosanoids derived from EPA and DHA
may reduce airway inflammation and bronchoconstriction, and thus reduce the
risk of respiratory disease.
The derivatives from the lung’s eicosanoids play an important role in
pulmonary function. Evidence has suggested that eicosanoids have an influence
on pulmonary edema, impaired gas exchange and immune responses associated
with lung injuries. Exposure to allergens has been shown to stimulate LTB4
release from tracheal epithelium and alveolar macrophages, which act as potent
activators of neutrophils (Meydani et al., 1992). Matsuyama et al. (2005) found
that nutritional support with an ALA-rich diet decreased serum and sputum levels
of LTB4.
There was a decreased production of PGE2 and TXB2 when dietary ALA
supplied as flaxseed oil was added to the diets of chickens (Craig-Schmidt et al.,
1987). Chickens were chosen as the animal model for dietary manipulation of
lung eicosanoids based on a previous report that indicated chickens fed diets
deficient in essential fatty acids developed pulmonary diseases (Hopkins et al.,
1963).
PUFAs may mitigate the development of bronchopulmonary dysplasia
(BPD), the most common type of chronic lung injury seen in pre-term infants
receiving oxygen therapy. In the pathogenesis of BPD, neutrophils release ROS
and proteases, which eventually lead to pulmonary fibrosis. Studies have shown
that rats subjected to hypoxia and then fed fish oil had less pulmonary fibrosis by
modifying lung injury due to hyperoxia (D’Ambola et al., 1991).
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Information concerning dietary manipulation of pulmonary eicosanoids is
limited. Therefore, our research determined if dietary ω-3 PUFAs have the
potential to act as modulators of eicosanoid biosynthesis in the respiratory system.
However, before ω-3 PUFAs are added to the diet for health benefits, it is
important to assess any potential risks associated with increased ω-3
consumption.
3.8

Oxidative stability
The effect of ω-3 PUFA intake on lipid peroxidation has produced

inconsistent results of increased oxidation (Song et al., 2000; Song and
Miyazawa, 2001; Yuan and Kitts, 2003), no effect on oxidation (Calviello, 1997)
and even decreased oxidation (Demoz et al., 1992). DHA and EPA are highly
susceptible to peroxidation due to their double bonds. DHA is more readily
oxidized than ALA, LA and AA (Song et al., 2000). Song et al. (2000) found
that feeding DHA-containing oil to healthy rats increased tissue DHA deposition
and decreased the amount of the antioxidant, α-tocopherol, in target membranes
of the liver and kidney. These results suggest that ω-3 PUFA supplementation
may require addition of antioxidants to prevent tissue damage due to lipid
peroxidation.
The impact of ROS may be especially important in the lungs because of its
surface area and its exposure to higher oxygen levels than other tissues. The lung
has several antioxidant defense systems that act to oppose destructive oxidation.
Several of these antioxidants are superoxide dismutase (SOD), catalase and
glutathione peroxidase (GSH-Px) (Day, 2007). According to Demoz et al. (1992),
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GSH-Px and catalase activity increased in healthy mice after gastric intubation
with EPA. However, Yuan and Kitts (2003) found that GSH-Px activity
decreased and lipid oxidation increased in the livers of MO-fed rats.
Because the lungs are highly susceptible to oxidation due to its physical
structure and function, it is important to investigate dietary fatty acids and their
potential anti-inflammatory role in the lungs and oxidative stability.
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4

MATERIALS AND METHODS
4.1

Animals and Diets

All animal procedures used in this study conformed to the National Research
Council (NRC) Guide for the Care and Use of Laboratory Animals (NRC, 1996). The
protocol for this study was approved by the Institutional Animal Care and Use
committee at West Virginia University. Growing (age 28 days) female Sprague-Dawley
rats (n=60) were obtained from Hilltop Labs (Scottdale, PA). Growing rats were used
because PUFAs are known to play a role in the normal aging process of the lung
(Schwartz, 2000). Rats were individually housed in metabolic cages under conditions of
controlled temperature (21°C) and a 12-h light: dark cycle. During the 7 day
acclimation, all animals were given ad libitum access to deionized distilled water
(ddH2O) and the American Institute of Nutrition AIN-93G diet (Harlan Teklad, WI).
The AIN-93G was fed because it is a standard purified diet that meets the National
Research Council (1995) recommendations for growing rats.
After a 7-day acclimation diet, the rats were randomly assigned (n=10 rats/group)
to a high fat (12% by weight) diet consisting of either corn oil (CO), krill oil (KO),
flaxseed oil (FO), menhaden oil (MO), salmon oil (SO) or tuna oil (TO). SO, TO, KO
and FO were chosen as commonly consumed sources of ω-3 PUFAs. FO was chosen
because it is the richest source of ALA (Cunnane, 1995). However, data suggests that
the biological conversion of ALA to the ω-3 LC-PUFAs, EPA and DHA, is low
(Simopoulos, 2008) and thus, FO may elicit less biological activity than fish oils rich in
EPA and DHA. TO was chosen for its high DHA content and salmon oil for its high
EPA content. TO, SO and FO were generously donated by Jedwards International Inc.

19

(Quincy, MA). MO is frequently used in research and is a ω-3 PUFA source used in
dietary fish oil supplements. MO was purchased from Omega Protein Inc (Houston,
TX).
In fish and plant sources, the ω-3 PUFAs are mainly associated with triglycerides.
However, KO fatty acids are mainly in the form of phospholipids (Gigliotti et al., 2010),
and was included because ω-3 PUFAs associated with phospholipids have been
suggested to be more bioavailable and more stable against lipid peroxidation than fatty
acids associated with triglycerides (Song et al., 2000). KO was purchased from
Enzymotec Ltd., Morristown, NJ.
Diet composition is shown in Table 1. Treatment diet was formulated based on
the AIN-93G formulation using 12% instead of 7% lipid by weight. The 12% lipid dose
was chosen because it represents the typical high-fat western diet. All diets were
adjusted to have comparable amounts of kilocalories and percentage of fat. CO (0.2%)
was added to 10% MO or KO in order to meet the National Research Council
recommended level of essential fatty acid, LA. Fatty acid composition of dietary oils is
shown in Table 2. Rats were fed 15 g diet/day and provided deionized distilled water
(ddH2O) ad libitum throughout the 8-week feeding study. Fresh diet was provided daily.
Body weight, food intake, and water consumption were measured weekly. At the end of
the 8-week study, rats were euthanized by CO2 inhalation and weighed, and tissues were
dissected and weighed. Tissues were stored at -80°C until analyzed.
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4.2

Lung Fatty Acid Composition
4.2.1 Lipid Extraction
Lipids were extracted from the right lung tissue according to the method

by Bligh and Dyer (1959). Briefly, 48 µl nonadecenoic acid (19:1) was added as
an internal standard to weighed samples (0.5 g). Lung homogenate was prepared
by adding weighed samples to Tris/EDTA buffer (pH 7.4). The Tris retains the
pH of the homogenate and the EDTA binds divalent cations which is important in
preserving the sample. A chloroform: methanol: acetic acid (2:1:0.15 v/v/v)
solution was added to the samples. Samples were centrifuged at 900 x g for 10
min. at 10°C and the bottom chloroform layer collected. The collected
chloroform layer was filtered through 1-phase separation filters to remove any
remaining water and precipitated material. The remaining layer was mixed with
chloroform: methanol (4:1 v/v) and centrifuged at 900 x g at 10°C. The
chloroform layer was then collected and filtered. The extracted lipid was dried
under nitrogen gas.
4.2.2 Fatty Acid Methylation
The extracted lipid samples were transmethylated according to Fritsche
and Johnston (1990). Briefly, extracted fatty acids were methylated by adding 4%
H2SO4 in anhydrous methanol to the dried extracted lipid samples followed by
incubation in a 90°C water bath for 60 min. Samples were cooled to room
temperature and 3 mL of double distilled H2O was added to stop the reaction.
Chloroform was added to the methylated samples and centrifuged at 900 x g for
10 min at 10°C. The chloroform layer was then filtered through anhydrous
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Na2SO4 to remove any remaining H2O. Samples were dried under nitrogen gas.
Dried samples were diluted in iso-octane to a concentration of 5 mg FAME (fatty
acid methyl esters)/mL iso-octane.
4.2.3 Fatty Acid Analysis
FAME samples were analyzed by gas chromatography (CP-3800, Varian,
CA) using an initial temperature of 140°C held for 5 min and then increased 1°C
per minute to a final temperature of 220°C. A wall-coated open tubular (WCOT)
fused silica capillary column (Varian Inc., Walnut Creek, CA) was used to
separate FAMEs with CP-Sil 88 as the stationary phase. Nitrogen was used as the
carrier gas and total separation time was 110 min. Quantitative 37 Component
FAME Sigma Mix (Supelco, Bellefonte, PA) was used as a standard to identify
fatty acids. Fatty acids were quantified using peak area counts and retention time.
4.3

RNA Isolation and Gene Expression
Gene expression of inflammation and antioxidant enzymes were

measured by isolating total RNA from lung tissue using the mirVana™ miRNA
Isolation Kit (Ambion Inc, Foster City, CA) according to the manufacturer's
instructions for total RNA isolation. The concentration of total RNA was
quantified using a NanoDrop 1000 spectrophotometer (Thermo 217 Scientific,
Waltham, MA). RNA integrity was assessed by agarose gel electrophoresis.
First-strand complementary DNA (cDNA) was synthesized using the SuperScript
III First-Strand Synthesis System (Invitrogen, Carlsbad, CA), according to the
manufacturer's instructions with oligo(dT)20 and 600 ng of RNA.
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To determine cyclooxygenase II (COX II), 5-lipoxygenase (5-LOX),
superoxide dismutase (SOD), catalase (CAT), and glutathione-peroxidase (GSHPx) gene expression, cDNA were amplified in quadruplicate by RT-qPCR using
an ABI 7500 Real-Time PCR System (Applied Biosystem) in a 5 μl reaction
volume using 2.5 μl 2X SYBR Green PCR Master Mix (Applied Biosystems,
Carlsbad, CA) with 100 nM of each primer and 1 μL of diluted 1:10 cDNA
sample.
The primer sequence for rat COX-II (Ptgs2, NM_017232) was (forward 5’
CGGAGGAGAAGTGGGTTTTAG 3’, and reverse 5’
TGAAAGAGGCAAAGGGACAC 3’), 5-LOX was (forward 5' – CCA TCA
AGA GCA GGG AGA AA – 3', reverse 5' – CAT AGT TGG AGG AGC GTT
GG – 3'), Zinc/Copper (Zn/Cu SOD) SOD 1 was (forward 5’ – GGT CCA CGA
GAA ACA AGA TGA - 3’, reverse 5’ – CAA TCA CAC CAC AAG CCA AG 3’), CAT was (forward 5’ – TGT TGA ATG AGG AGG AGA GGA - 3’, reverse
5’ – TTC TTA GGC TTC TGG GAG TTG - 3’), and GSH-Px was (forward 5’ GAT ACG CCG AGT GTG GTT T - 3’, reverse 5’ - TCT TGA TTA CTT CCT
GGC TCC T - 3’). The housekeeping gene GAPDH was used as an internal
reference (forward 5’ - TCA AGA AGG TGG TGA AGC AG - 3’, reverse: 5’ CCT CAG TGT AGC CCA GGA TG - 3’).
The program used for qRT-PCR amplification consisted of an initial
temperature at 50°C for 2 min followed by an initial denaturation for 10 min at
95°C and 40 PCR cycles. Each cycle comprised a melting step at 95°C for 15 sec
followed by a joint annealing/extension step at 60°C for 1 min. Specificity of
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amplification was assessed by a melting curve of each amplicon, and visualization
of the expected fragment size on 3% agarose gel. Data were expressed as relative
gene expression to the control after normalization to the GAPDH housekeeping
gene. Relative Expression Software Tool (REST) 2009 (Corbett Research Pty Ltd
and Pfaffl, 2009) was used for gene expression calculation.
4.4

Measurement of Eicosanoids
Since TXB2 and PGE2 derived from ARA are a short-lived molecule, the

stable metabolites 11-dehydro TXB2 and 13,14-dihydro-15-keto PGE2,
respectively, were measured.
Pooled 7 d urine samples were collected during the final week of the 8 wk
feeding study. Rats were individually housed in metabolic cages to collect urine.
Ascorbic acid (0.1%) was added to the urine collection tubes as a preservative,
and mineral oil (1 mL) was added to prevent evaporation. Pooled 7 d urine
samples were centrifuged at 1,500 g for 10 min at 4oC. Following centrifugation,
urine samples were aliquoted into clean tubes.
Urinary 11-dehydro TXB2 and 13,14-dihydro-15-keto PGE2 were
determined using a commercially available enzyme immunoassay kit according to
the manufacturer’s instructions (Cayman Chemical, Ann Arbor, MI). Absorbance
was determined at wavelength 405 nm using a Spectramax Plus microplate reader
(Molecular Devices, Sunnyvale, CA). All samples were performed in duplicates.
4.5

Measurement of Oxidative Stability
To determine lipid peroxidation, Thiobarbituric Acid Reactive Substances

(TBARS) were measured in serum using a commercially available EIA kit
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(Cayman Chemical, MI). To determine TBARS, samples were mixed with
sodium dodecyl sulfate (SDS) solution and a color reagent consisting of acetic
acid, sodium hydroxide, and thiobarbituric acid (TBA). Samples incubated for 1h
in a 90°C water bath, and then were placed in an ice bath for 10 min to stop the
reaction. Following centrifugation for 10 min at 1,600 x g at 4°C, absorbance was
read at 540 nm using a Spectramax Plus microplate reader (Molecular Devices,
CA). Samples were determined in duplicate. TBARS values were expressed as
µM/malondialdehyde (MDA).
Total antioxidant capacity (TAC) was measured using a commercially
available antioxidant assay colorimetric assay kit (Cayman Chemical, Ann Arbor,
MI). Briefly, serum TAC was determined by diluting serum samples 1:20 v/v
with 5 mM potassium phosphate buffer (pH 7.4) containing 0.9% sodium chloride
and 0.1% glucose. Lung homogenates were prepared in 1 mL of 5 mM potassium
phosphate buffer (pH 7.4). Absorbance was determined at 750 nm using a
Spectramax Plus microplate reader (Molecular Devices, Sunnyvale, CA). All
samples were determined in duplicate and values were expressed as nM Trolox
equivalents.
4.6

Statistical analyses
Animal number was determined by performing a power analysis with

power of 0.80 and α=0.05. All results are expressed as mean ± SEM. Data was
analyzed by one-way analysis of variance (ANOVA) to determine the differences
among the diet treatment groups. Post hoc multiple comparison tests were
performed using Tukey’s (parametric) or Kruskal-Wallis (non-parametric) test.
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Results with p-values of < 0.05 are considered significant. All statistical analyses
were performed using Sigma Stat (Abacus Concepts, Berkeley, CA).
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5

RESULTS
5.1

Body and Lung Weights
Over the 8 week study, rats showed no significant difference in final body

weight, total body weight gain and total food intake (Table 3). The absolute lung
weights of the rats fed SO were lower (P=0.001) than rats fed CO, FO, KO or MO
(Fig. 1A). Relative lung weights were lower (P=0.001) in rats fed SO compared
to rats fed CO, KO or MO (Fig. 1B). Relative lung weights were also lower
(P=0.002) in rats fed TO compared to rats fed CO.
5.2

Lung Lipids and Fatty Acid Composition
The lipid content of the lungs of rats fed CO was 3.4% lipid, 5.3% for FO,

3.6% for KO, 4.9% for MO, 3.7% for SO and 3.8% for TO. The percent of lipid
in the lung of rats fed FO was significantly higher than rats fed CO, KO, SO or
TO (Fig. 2). The percent lipid in rats fed MO was higher than rats fed CO, KO or
SO.
Table 4 shows the lung fatty acid composition of rats fed different sources
of -3 PUFAs. ALA was only detectable in the lungs of rats fed FO EPA was
higher in the rats fed KO compared to all treatment diets, except for SO. Rats fed
SO had higher (P<0.001) lung EPA content than CO-fed rats. Lung DHA content
was higher in rats fed TO compared to rats fed CO (P<0.001), FO (P<0.001) or
MO (P=0.04). Lung DHA content was higher in the rats fed SO than rats fed CO
(P=0.001) or FO (P=0.02). DHA content was also higher in the lungs of rats fed
KO than rats fed CO (P<0.001) or FO (P=0.006).
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Rats fed CO had the highest (P<0.001) lung LA concentration among the
treatment groups. FO had a significantly higher lung LA concentration than rats
fed the fish oil diets MO (P=0.01), SO (P=0.004) or TO (P=0.003). Rats fed CO
had the highest lung AA concentrations (P<0.001) among the treatment groups
(Table 4).
The ω-6/ω-3 ratio was 57:1 for rats fed CO, 2:1 for FO-fed rats, 1:1 for
KO, MO, SO, and TO-fed rats (Table 4).
5.3

Eicosanoid Metabolism
The relative expression of 5-LOX was significantly up-regulated

(P=0.007) in rats fed FO compared to CO-fed rats (Figure 3A). There were no
treatment differences in the expression of COX II (Figure 3B).
No significant differences (P<0.05) were observed in the concentration of
urinary TXB2 (Figure 4A) or PGE2 metabolites (Figure 4B) among the dietary
treatment groups.
5.4

Oxidative Stability
Serum TBARS were lower (P<0.001) in rats fed SO or TO compared to

rats fed CO, KO or MO (Table 4). There were no significant differences in serum
or lung tissue antioxidant capacity among the dietary treatment groups.
Expression of the antioxidant defense enzyme, superoxide dismutase was
significantly down-regulated (P=0.01) in TO-fed rats compared to rats fed CO
(Figure 5C). There were no treatment differences in the expression of CAT
(Figure 5A) or GSH-Px (Figure 5B).
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6

DISCUSSION
The lung is an organ that is constantly exposed to inflammation and oxidative

stress due to its vast surface area (Schwartz, 2000). Most studies have used disease
animal models or an exogenous trigger such as the bacterial endotoxin,
lipopolysaccharide, to activate immune responses in the lungs (Calder, 2003). There
have been few studies using healthy rodents as models for detecting the effects of diet on
tissue ω-3 PUFA content, specifically in the lungs. In addition, most studies in healthy
animals use neonates. Yet, the prevalence of respiratory diseases among adults is
increasing (Christie et al., 1999). Suarez et al. (1996) found that weanling rats fed ω-3
PUFAs resulted in incorporation of ω-3 PUFAs into the lungs. This has important
implications because the ability of ω-3 PUFAs to modulate lung fatty acid composition
and eicosanoid activity may ameliorate the normal decline in lung function associated
with age and may be protective against risk of lung damage and disease.
In our study, rats fed different sources of ω-3 PUFAs had different lung weights.
Rats fed SO or TO had lower (P<0.01) relative lung weights compared to rats fed CO.
Pankhania and Bakhle (1985) found increased lung weights in rats treated with a single
dose of α-naphthylthiourea, a rodenticide. The increased lung weight was due to edema
caused by an increased production of 2-series prostaglandins and thromboxanes from
AA. Therefore, lower lung weights in rats fed SO and TO may be protective since diets
rich in -3 PUFAs can competitively inhibit synthesis of pro-inflammatory 2-series
eicosanoids (i.e. PGs and TXs) derived from AA.
In our study, a high fat diet (~27% by kcals) was used to reflect the higher total
fat intake typical of the Western diet (~33% by kcals). The present study showed that the
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FA composition of the lungs reflected dietary intake in growing healthy rats fed a high fat
diet. Rats fed FO, which has the highest dietary ALA content, had the highest lung ALA
deposition. Rats fed KO, which has the highest dietary EPA content, had the highest lung
EPA deposition compared to all diet groups, except rats fed SO. SO may be an exception
because it had the highest dietary EPA to DHA ratio (3:1) of the ω-3 PUFA sources.
Lung DHA deposition was higher in rats fed TO, which has the highest dietary DHA
content, compared to rats fed CO, FO or MO. Dietary DHA was not detectable in CO
and FO. Of the marine oil sources, MO had the lowest dietary DHA content.
De novo synthesis of ω-3 LC-PUFAs has been reported to occur in the liver,
mammary gland, and adipose tissue (Ratnayake et al., 2009). De novo synthesis of the ω3 LC-PUFAs, EPA and DHA, in the lungs was indicated by their presence in CO and FOfed rats. Rats fed CO and FO containing dietary ALA, but no dietary EPA or DHA,
resulted in EPA and DHA deposition in the lungs. However, pre-formed EPA and DHA
in marine sources resulted in significantly higher lung ω-3 PUFA content than de novo
synthesis in CO and FO-fed rats. Palombo et al. (1994) reported that continuous enteral
feedings enriched with fish oil significantly increased the ω-3 PUFA concentration of rat
lung parenchymal tissue, macrophage and surfactant phospholipids in rats.
Efficient conversion of LA to ω-6 LC-PUFAs in lung tissue was indicated by rats
fed CO containing no detectable dietary AA having significantly higher AA deposition
compared to rats fed FO, KO, MO, SO and TO. Rats fed FO, KO, MO and SO
containing no detectable dietary AA also resulted in tissue AA, but lower (P<0.001)
amounts than rats fed CO. This may be due to more LA substrate available for
conversion to AA in CO-red rats.
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Feeding FO or marine oils increased ω-3 PUFAs resulting in a reduced ω-6 to ω-3
ratio. The ω-6 PUFA to ω-3 PUFA ratio was 57:1 for rats fed CO, 2:1 for FO-fed rats,
1:1 for KO-fed rats, 1:1 for MO-fed rats, 1:1 for SO-fed rats and 1:1 for TO-fed rats. A
serum ω-6 to ω-3 ratio of 4:1 is suggested for optimal health (Simopoulos, 2008),
however recommended tissue ω-6 to ω-3 ratios are unknown.
The observed decreases in the ω-6 to ω-3 ratios are significant because the FA
composition of the lungs may influence a cascade of cellular responses. Increasing ω-3
PUFAs, ALA and EPA results in a decreased production of pro-inflammatory
eicosanoids, derived from ω-6 PUFAs, by competing with LA and AA (Calder, 2003;
Schwartz, 2000). In our study, lung AA was significantly decreased in rats fed FO and
marine oils in comparison to f rats fed CO. There was no significant difference in lung
AA content in rats fed FO compared to the marine oils.
The lung manifests significant COX II and 5-LOX activity with their eicosanoid
products playing an important role in pulmonary function (Meydani et al., 1992). AAderived eicosanoids such as TXA2 promotes bronchoconstriction and PGE2 and LTB4 are
produced by mast cells that mediate pulmonary inflammation (Calder, 2003). Meydani et
al. (1992) found that healthy mice, 3 or 24 months of age, fed marine oils had lower
synthesis of TXB2 and PGI2. Therefore, synthesis of lung eicosanoids can contribute to
pathological changes occurring in the respiratory system during the normal aging process.
In our study, there were no significant differences (P<0.05) observed in the concentration
of urinary TXB2 or PGE2 among the dietary treatment groups. Due to the numerous
eicosanoids and the difficulty of measuring these short-lived molecules, we also
determined gene expression of COX II and 5-LOX.
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The FA composition of the lungs may influence the expression of various genes.
Patterns in gene expression can reveal genetic predisposition and physiological condition.
To our knowledge, there have been few feeding studies investigating the effect of ω-3
PUFAs on inflammatory gene expression in the lungs. Most of these studies have used
diseased mammalian models with the objective not on prevention, but on resolution.
Results have reported that feeding patients ω-3 PUFAs decreased their amount of
complications and infections, as well as decreased severity, progression and length of
hospital stay (Calder, 2003).
In our study, ω-3 PUFAs as FO had effects in the lung. The expression of 5-LOX
was significantly up-regulated (P=0.007) in rats fed FO compared to CO-fed rats. Of the
dietary treatments, FO has the highest ALA content and resulted in significantly higher
ALA deposition in the lungs. Due to the high ALA content, increased expression of 5LOX would result in the production of 5-series leukotrienes that are less biologically
potent than the 3-series leukotrienes (Calder, 2003). Craig-Schmidt et al. (1987) found a
decreased production of PGE2 and TXB2 when dietary ALA supplied as flaxseed oil was
added to the diets of chickens.
Increasing tissue ω-3 PUFA exerts beneficial physiological effects by influencing
cell membrane fluidity, membrane-bound receptors, signaling molecules, and gene
expression (Deckelbaum et al., 2006). However, higher tissue unsaturation needs to be
considered since a greater number of double bonds may increase tissue susceptibility to
lipid peroxidation. Therefore, DHA is particularly susceptible to lipid peroxidation due
to its high degree of unsaturation (Song et al., 2011). The effect of ω-3 PUFA intake on
lipid peroxidation has produced inconsistent results of increased oxidation in the liver and
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kidney (Song et al., 2000; Song and Miyazawa, 2001; Yuan and Kitts, 2003), no effect on
oxidation in plasma and red blood cell membranes (Calviello, 1997) and even decreased
oxidation in mice livers (Demoz et al., 1992).
Our study showed rats fed TO, the highest dietary source of DHA or SO with the
high DHA digestibility of the fish oils (Tou et al., 2011) resulted in lower (P<0.001)
serum TBARS compared to all diet groups, except FO-fed rats. Oxidative stress occurs
when accumulation of oxidative products overwhelms the body’s antioxidant capacity.
TAC measures endogenous antioxidant, dietary antioxidant and interactions between
antioxidants (Young, 2001). In our study, serum and lung homogenate TAC was not
significantly different among the diet groups. Expression of the antioxidant defense
enzyme, superoxide dismutase was down-regulated (P=0.01) in TO-fed rats compared to
rats fed CO. Probably due to less TBARS in TO-fed rats, there was no detectable
expression or up-regulation of the level of antioxidants. Antioxidants such as alphatocopherol are routinely added to marine oils due to their high EPA and DHA, but not
FO.
Dietary TO has an EPA/DHA ratio of 1:2 and had a higher (P<0.001) lung DHA
content compared to rats fed CO. DHA is more readily oxidized than ALA, LA and AA
due to the presence of six double bonds (Song et al., 2000). SOD1 is an enzyme located
in the cytosol that catalyzes the breakdown of superoxide into oxygen and hydrogen
peroxide (McKee and McKee, 2009. Thus, they are an important antioxidant defense in
nearly all cells exposed to oxygen. KO showed no differences in antioxidant gene
expression despite suggestion of increased oxidative stability due to it being in the
phospholipid form (Song et al., 2000).
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7

SUMMARY AND CONCLUSION
The present study evaluated the affect of popular sources of ω-3 PUFAs on lung

fatty acid composition and gene expression. The high fat diet (~27%) by kcals) was used
to reflect the higher total fat intake typical of the Western diet (~33% by kcals). Our
study showed that the FA composition of the lungs reflected dietary intake in growing
healthy rats fed high fat (12% by weight) diets.
In our study, there were no significant differences observed in the concentration
of serum TXB2 or urine PGE2 among the dietary treatment groups. Due to the numerous
eicosanoids and the difficulty of measuring these short-lived molecules, we also
determined gene expression of COX II and 5-LOX. The relative expression of 5-LOX
was significantly up-regulated (P=0.007) in rats fed FO compared to CO-fed rats.
Decreased serum TBARS in SO and TO-fed rats showed that these diets were
protective against oxidative stress. Due to less TBARS in TO-fed rats, there was no
detectable expression or up-regulation of the antioxidants. This is especially important in
the lungs because of their increased susceptibility to oxidation compared to other organs.
These results are significant because the increase in ω-3 PUFAs in lung tissue
may affect the risk of lung damage, and in turn, susceptibility to lung diseases by altering
gene expression of inflammation and oxidative stability. Few studies have reported on
healthy non-neonate animals. Our study is novel because we saw changes in healthy
animals that were past weaning age. Considering efficient tissue incorporation with the
least amount of tissue lipid peroxidation, FO, SO and TO appear to be the best sources of
ω-3 PUFAs most favorable to lung health.
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8

FUTURE RESEARCH
The goal of future research is to determine novel interventions that have the

ability to prevent or modify the course of lung disease that is increasing in prevalence
among infants and adults (Christie et al., 1999). Further research into dietary
consumption of ω-3 PUFAs for the prevention of lung inflammation and disease is a
promising area of contribution.
Our study would benefit from looking at more measurements indicative of
inflammation in the lung. An example of this would be the 5-LOX-derived eicosanoid,
leukotriene at the tissue level versus systemic level. However, it is difficult to test
hormones due to their short-lived nature, and only a limited number of laboratories have
the developed methods for performing these measurements.
Instead, gene expression of regulators of inflammation may be determined. The
family of nuclear receptors, peroxisome proliferator-activated receptors (PPARs) is
expressed in various types of cells that play important roles in inflammation and
immunity. PPARα is abundant in macrophages, monocytes and endothelial cells, and
PPARγ is abundant in alveolar epithelial cells and the bronchial sub-mucosa (Simon et
al., 2006). The transcription factor nuclear factor kappa B (NF-кB) is a critical regulator
of innate immune responses, including the pro-inflammatory cytokines (Uddin and Levy,
2010). Cheng et al. (2007) indicated that inhibition of NF-кB activation in airway
epithelium reduces lung inflammation and injury induced by the gram-negative bacteria
lipopolysaccharide. Measuring NF-кB in a healthy animal lung model has yet to be
researched.
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Another exciting area of research in ω-3 PUFAs and lung health are pro-resolving
mediators. Resolvins are a novel class of mediators generated from EPA and DHA that
act to promote resolution of inflammation (Uddin and Levy, 2010). The pulmonary
inflammatory response can either progress to chronic lung inflammation or complete
resolution. According to Uddin and Levy (2012), resolvins have the ability to restore
lung homeostasis by acting in a cell-specific manner to reduce pulmonary inflammation
and promote tissue catabasis. It would be interesting to investigate whether different
dietary sources of ω-3 PUFAs affect the concentration of resolvins in the lungs.
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Table 1: Diet Composition
Ingredients (g/Kg diet) 1

CO2

FO

KO

MO

SO

TO

Casein

200

200

200

200

200

200

3

3

3

3

3

3

Corn Starch

347.5

347.5

347.5

347.5

347.5

347.5

Maltodextrin

132

132

132

132

132

132

Sucrose

100

100

100

100

100

100

0

120

118

118

120

120

Corn Oil

120

0

2

2

0

0

Cellulose

50

50

50

50

50

50

Mineral Mix, AIN-93G-MXa

35

35

35

35

35

35

Vitamin Mix, AIN-93-VXa

10

10

10

10

10

10

Choline Bitartrate

2.5

2.5

2.5

2.5

2.5

2.5

L-Cystine

Source (Marine/Plant) Oil

1

Based on the AIN-93G vitamin and mineral mixes (Reeves et al., 1993).

2

Abbreviations are CO, corn oil; FO, flaxseed oil; KO, krill oil; MO, menhaden oil; SO,
salmon oil; TO, tuna oil.
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Table 2: Fatty Acid Profile of Dietary Oils1
CO2

FO

KO

MO

SO

TO

LA; 18:2

618.37

163.25

30.05

4.49

24.98

21.98

AA; 20:4

0

0

0

0

0

26.84

ALA; 18:3

11.55

584.83

19.71

18.9

9.36

10.06

EPA; 20:5

0

0

323.62

60.65

99.39

117.98

DHA; 22:6

0

0

115.46

26.53

29.37

405.34

EPA:DHA

n/a

n/a

3:1

3:1

3:1

1:2

ω-6:ω-3

73:1

1:3

1:33

1:48

1:23

1:12

ω-6 PUFAs

ω-3 PUFAs

1

Results are given as mg FA/ mL lipid
Abbreviations are CO, corn oil; FO, flaxseed oil; KO, krill oil; MO, menhaden oil; SO, salmon
oil; TO, tuna oil; PUFAs, polyunsaturated fatty acids; LA, linoleic acid; AA, arachidonic acid;
ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid
2
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Table 3: The Effect of Feeding Growing Female Rats Fed Different Sources of Omega-3 Polyunsaturated Fatty Acids on Body Weight,
Weight Gain and Food Intake1
Treatment

CO2

FO

KO

MO

SO

TO

Final body weight (g)

214.9±20.1

239.6±26.1

231.7±20.8

241.5±45.5

215.5±32.5

234.9±25.9

Total Weight Gain (g)

76.0 ± 7.4

103.8 ± 8.1

98.4 ± 6.1

107.6 ± 12.5

86.0 ± 8.4

106.0 ± 6.7

Total Food Intake (g)

750.1 ± 12.5

762.9 ± 14.3

767.4 ± 10.9

761.2 ± 17.6

706.8 ± 17.4

738.3±16.4

1
2

Values are the mean ± SEM of n=10 rats/group
Abbreviations are CO, corn oil; FO, flaxseed oil; KO, krill oil; MO, menhaden oil; SO, salmon oil; TO, tuna oil
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Figure 1:

Absolute Lung Weights (g)

A) Absolute lung weights (g) of growing female rats fed different sources of omega-3 polyunsaturated fatty acids.

Treatment Diet
The different letters a, b, indicate significant differences at P<0.05 by one-way ANOVA followed by Tukey’s test. Values
are the mean ± SEM of n=10 rats/group.
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Relative Lung Weights (mg/100g)

B) Relative lung weights (mg/100g bwt) of growing female rats fed different sources of omega-3 polyunsaturated fatty acids.

Treatment Diet
The different letters a, b, c indicate significant differences at P<0.05 by one-way ANOVA followed by Tukey’s test. Values
are the mean ± SEM of n=10 rats/group.
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Lipid Content (%)

Figure 2: Percent lipid in the lungs of growing female rats fed different sources of omega-3 polyunsaturated fatty acids. 1

Treatment Diet
1

The different letters a, b, c indicate significant differences at P<0.05 by one-way ANOVA followed by Tukey’s test. Values
are the mean ± SEM of n=10 rats/group
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Table 4. Fatty acid composition in the lungs of growing female rats fed different sources of omega-3 polyunsaturated fatty
acids.1
Treatments
Fatty Acids Measurement

2

SFA

CO
733.0±91.4

FO
666.0±82

KO
944.0±165.2

MO
605.0±104.1

SO
710.0±128

TO
619.0±109.4

Palmitic Acid; 16:0

535.0±67.3

483.0±60.6

735.0±138.0

464.0±85.1

543.0±99.2

466.0±83.9

Stearic Acid; 18:0

198.0±24.1

183.0±21.4

209.0±27.2

141.0±19.0

167.0±28.8

153.0±25.5

b

b

211.5±34.5

b

b

257.5±40.7b

a

ω-6 PUFA

913.0±118.4

LA; 18:2

286.0±45.0a

172.0±23.4b

92.5±27.8b,c

50.5±10.1c

37.7±7.1c

35.3±7.4c

AA; 20:4

627.0±73.4a

269.0±36.2b

228.0±42.6b

161.0±24.4b

220.0±36.2b

273.0±42.5b

ω-3 PUFA

16.0±9.9b

205.3±42.1a

289.6±64.9a

156.2±26.6a

249.4±43.4a

257.5±40.7a

ALA; 18:3

ND

112.0±27.6

ND

ND

ND

ND

c

EPA; 20:5

4.7±4.7

DHA; 22:6

11.3±5.2c

441.0±59.6

48.4±6.1

b,c

44.9±8.4c

320.5±70.4

109.0±24.9

a

176.0±35.4a,b

46.2±8.2

b,c

110.0±18.4b,c

258.0±43.3

90.5±14.8

a,b

158.0±27.7a,b

39.7±5.5b,c
217.0±34.4a

57:1
2:1
1:1
1:1
1:1
ω-6:ω-3
Values are expressed as mean (μg FA/g tissue) ± SEM of n=10 rats/group. Different superscript letters a, b, c within the same
rows indicate significant differences at P<0.05 by one-way ANOVA followed by Tukey’s test (parametric) or Kruskal-Wallis
test (non-parametric).
2
Abbreviations are: CO, corn oil; FO, flaxseed oil; KO, krill oil; MO, menhaden oil; SO, salmon oil; TO, tuna oil.; SFA,
saturated fatty acids; PUFA, polyunsaturated fatty acids; ND, not detectable; LA, linoleic acid; AA, arachidonic acid; ALA,
alpha-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.
1
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1:1

A)
14

*

5-LOX
Relative Expression Ratio

12
10
8
6

4
2
0
CO

FO

KO

MO

SO

TO

SO

TO

Treatment Diet
B)
1.6

COX II
Relative Expression Ratio

1.4
1.2
1
0.8
0.6
0.4
0.2
0
CO

FO

KO

MO

Treatment Diet
Figure 3. The effect of feeding growing female rats fed different sources of omega-3
polyunsaturated fatty acids on gene expression of A) 5-lipoxygenase (5-LOX) and B)
cyclooxygenase II (COX II). Values are relative mRNA expression to corn oil treatment
(control) after normalization to the GAPDH housekeeping gene expressed as ratios.
Abbreviations are: CO, corn oil; FO, flaxseed oil; KO, krill oil; MO, menhaden oil; SO,
salmon oil; TO, tuna oil.
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Figure 4:
A) Urine TXB2 Metabolite Concentrations (pg/mL) in Young Growing Rats Fed
Different Sources of Omega-3 Polyunsaturated Fatty Acids.

Urine TXB2 Metabolite (pg/mL)

3000
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B) Urine PGE2 Metabolite Concentrations (ug/d) in Young Growing Rats Fed
Different Sources of Omega-3 Polyunsaturated Fatty Acids.
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CAT
Relative Expression Ratio

A)

2
1.5
1
0.5
0
CO

FO

KO

MO

SO

TO

Treatment Diet

GSH-Px
Relative Expression Ratio

B)
1.2
1
0.8
0.6
0.4
0.2

0
CO

FO

KO

MO

SO

TO

Treatment Diet
C)

SOD1
Relative Expression Ratio

1.6

1.4
1.2
1
0.8

*

0.6

0.4
0.2
0
CO

FO

KO

MO

SO

TO
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Treatment Diet
Figure 5. The effect of feeding growing female rats fed different sources of omega-3
polyunsaturated fatty acids on gene expression of A) catalase (CAT), B)
glutathione-peroxidase (GSH-Px) and C) superoxide dismutase 1 (SOD1). Values are
relative mRNA expression to corn oil treatment (control) after normalization to the
GAPDH housekeeping gene expressed as ratios. Abbreviations are: CO, corn oil; FO,
flaxseed oil; KO, krill oil; MO, menhaden oil; SO, salmon oil; TO, tuna oil.

55

Table 5: Oxidative Stability Measurements in Young Growing Rats Fed Different Sources of Omega-3 Polyunsaturated Fatty Acids
Treatments

CO1
6.9±0.4a

FO
5.9±0.2ab

KO
6.5±0.3a

MO
6.8±0.3a

SO
5.1±0.3b

TO
5.2±0.2b

Serum TBARS (µM MDA)
Serum Antioxidant Capacity
1.5±0.2
1.1±0.1
1.3±0.1
1.5±0.2
1.1±0.2
1.2±0.2
(mM Trolox)
Lung Antioxidant Capacity
0.1±0.05
0.08±0.05
0.08±0.02
0.1±0.04
0.1±0.04
0.1±0.05
(mM Trolox/g Tissue)
1
Abbreviations are CO, corn oil; FO, flaxseed oil; KO, krill oil; MO, menhaden oil; SO, salmon oil; TO, tuna oil; MDA, malondialdehyde.
Values are mean± SD. The different letters a, b, indicate significant differences and ab no significant difference at P<0.05 by one-way
ANOVA.
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